Gene · 10128
Papers1,499
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,499
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SLIRP differentially modulates RNA binding of pathogenic LRPPRC variants. | NAR Mol Med | 2026 | 42688402 | PubTator, text mining | PubMed |
| Mechanism of troxerutin-mediated regulation of EGLN3/LRPPRC in B[a]P-induced lung adenocarcinoma. | Int Immunopharmacol | 2026 | 42556279 | PubTator, text mining | PubMed |
| Correction: Bendless is essential for PINK1-Park mediated Mitofusin degradation under mitochondrial stress caused by loss of LRPPRC. | PLoS Genet | 2026 | 42555611 | PubTator, text mining | PubMed |
| LRPPRC deficiency impairs trophoblast function through disrupted phosphatidylinositol metabolism in recurrent pregnancy loss. | Hum Reprod | 2026 | 42515815 | PubTator, text mining | PubMed |
| Reduced LANCL1-AS1 in old human skeletal muscle diminishes mitochondrial activity, shortens mt-mRNA poly(A) tails, and suppresses myogenesis. | bioRxiv | 2026 | 42465395 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Disulfidptosis-Related Genes in Multiple Myeloma: Implications for Prognosis and Immune Microenvironment. | Acta Haematol | 2026 | 42461871 | PubTator, text mining | PubMed |
| Discovery of Novel LRPPRC Inhibitors Featuring a Biphenyl-Acylhydrazone Scaffold with Potent Broad-Spectrum Antitumor Activity. | J Med Chem | 2026 | 42441917 | PubTator, text mining | PubMed |
| Identifying potential drug targets for physical and cognitive frailty: an integrative analysis of CHARLS cohort, mendelian randomization, and gene colocalization. | Biogerontology | 2026 | 42337223 | PubTator, text mining | PubMed |
| Folding the message: mRNA structure as a regulatory layer of human mitochondrial gene expression. | Biochim Biophys Acta Mol Cell Res | 2026 | 42263953 | PubTator, text mining | PubMed |
Construction of an eight-disulfidptosis-related long non-coding RNA prognostic signature and mechanistic investigation of key molecule MKLN1-AS driving hepatocellular carcinoma progression via the miR-139-5p/LRPPRC axis. | Discov Oncol | 2026 | 42243619 | PubTator, text mining | PubMed |
| Molecular glue that stabilizes the LRPPRC-MET-G4 interaction complex to drive MET downregulation. | Nat Commun | 2026 | 42243089 | PubTator, text mining | PubMed |
| Two Siblings with LRPPRC Mutation: Mitochondrial Complex IV Deficiency: Case Report. | Mol Syndromol | 2026 | 42232680 | PubTator, text mining | PubMed |
| Mitochondrial translocation of immunostimulatory RNA RN7SL1 suppresses innate immune responses. | Acta Biochim Biophys Sin (Shanghai) | 2026 | 42178286 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A RNA methylation regulators for prognostic risk stratification and immune microenvironment characterization in colorectal cancer. | Open Med (Wars) | 2026 | 42109907 | PubTator, text mining | PubMed |
Leucine-rich pentatricopeptide repeat-containing protein silencing transcriptionally regulated by GATA-binding protein 3 has an anti-glioma effect by regulating glycolysis and ferroptosis by mediating N6-methyladenosine modification of protocadherin-7. | J Neuropathol Exp Neurol | 2026 | 42081257 | PubTator, text mining | PubMed |
| Disulfidptosis-related genes define a prognostic signature and novel therapeutic targets in Ewing's sarcoma through transcriptomic analysis and experimental validation. | Front Immunol | 2026 | 42064080 | PubTator, text mining | PubMed |
| Hyperglycemia impairs cognitive function by inducing mitochondrial damage through lactylation of LRPPRC at K223. | EMBO Mol Med | 2026 | 41942754 | PubTator, text mining | PubMed |
| Synergistic Anti-Tumor Activity of LRPPRC Inhibition and Dasatinib Through Dual Oxidative Phosphorylation Disruption. | Pharmaceuticals (Basel) | 2026 | 41901318 | PubTator, text mining | PubMed |
| A Pooled Blood Genome-Wide Association Study of Hypertension in Sindhi Families: Results from the DISFIN Study. | Genes (Basel) | 2026 | 41898884 | PubTator, text mining | PubMed |
| Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer. | Breast Cancer Res Treat | 2026 | 41885969 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10128/papers